Kodikaz Therapeutic Solutions Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Later Stage VC
- Latest Deal Amount
-
$3M
- Investors
-
8
Kodikaz Therapeutic Solutions General Information
Description
Operator of a genomic transfer delivery platform designed for both RNA and DNA delivery vectors. The company translates previously unknown cell-recognition and genomic integration mechanisms through the discovery of technologies derived from findings in human cancers and also generates both in vitro and in vivo data in oncology, including pancreatic, myeloma, and colorectal cancers, enabling clients to develop cell-specific gene transfer technologies into curative therapies.
Contact Information
Website
www.kodikaz.comCorporate Office
- 180 Varick Street
- 6th Floor
- New York, NY 10014
- United States
Corporate Office
- 180 Varick Street
- 6th Floor
- New York, NY 10014
- United States
Kodikaz Therapeutic Solutions Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Later Stage VC | 21-May-2024 | $3M | Completed | Pre-Clinical Trials | ||
| 1. Grant | 15-Aug-2021 | Completed | Pre-Clinical Trials |
Kodikaz Therapeutic Solutions Patents
Kodikaz Therapeutic Solutions Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4590309-A2 | Nucleic acid-based delivery systems and uses thereof | Pending | 29-Jul-2022 | ||
| WO-2024026466-A2 | Nucleic acid-based delivery systems and uses thereof | Inactive | 29-Jul-2022 | ||
| WO-2024026466-A3 | Nucleic acid-based delivery systems and uses thereof | Inactive | 29-Jul-2022 | ||
| CA-3239944-A1 | Receptor-mediated delivery of nucleic acids | Pending | 07-Dec-2021 | ||
| EP-4444880-A1 | Receptor-mediated delivery of nucleic acids | Pending | 07-Dec-2021 | C07K16/2833 |
Kodikaz Therapeutic Solutions Signals
Kodikaz Therapeutic Solutions Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alexandria Real Estate Equities | Real Estate | |||
| AmorChem | Venture Capital | Minority | ||
| Epidarex Capital | Venture Capital | Minority | ||
| Georgia Research Alliance | Not-For-Profit Venture Capital | |||
| GRA Venture Fund | Venture Capital | Minority |
Kodikaz Therapeutic Solutions FAQs
-
When was Kodikaz Therapeutic Solutions founded?
Kodikaz Therapeutic Solutions was founded in 2018.
-
Where is Kodikaz Therapeutic Solutions headquartered?
Kodikaz Therapeutic Solutions is headquartered in New York, NY.
-
What is the size of Kodikaz Therapeutic Solutions?
Kodikaz Therapeutic Solutions has 8 total employees.
-
What industry is Kodikaz Therapeutic Solutions in?
Kodikaz Therapeutic Solutions’s primary industry is Drug Discovery.
-
Is Kodikaz Therapeutic Solutions a private or public company?
Kodikaz Therapeutic Solutions is a Private company.
-
What is Kodikaz Therapeutic Solutions’s current revenue?
The current revenue for Kodikaz Therapeutic Solutions is .
-
How much funding has Kodikaz Therapeutic Solutions raised over time?
Kodikaz Therapeutic Solutions has raised $3M.
-
Who are Kodikaz Therapeutic Solutions’s investors?
Alexandria Real Estate Equities, AmorChem, Epidarex Capital, Georgia Research Alliance, and GRA Venture Fund are 5 of 8 investors who have invested in Kodikaz Therapeutic Solutions.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process